Wechselwirkungen · Adempas
Adempas 0.15 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 32
HOS-129081 · Präparat HOS-096659
Concomitant use with CYP1A1, UGT1A1 and UGT1A9 inhibitors From the recombinant CYP isoforms investigated in vitro CYP1A1 catalysed formation of riociguat’s main metabolite most effectively. The class of tyrosine kinase inhibitors was identified as potent inhibitors of CYP1A1, with erlotinib and gefitinib exhibiting the highest inhibitory potency in vitro. Therefore, drug-drug interactions by inhibition of CYP1A1 could result in increased riociguat exposure, especially in smokers (see section 5.2). Strong CYP1A1 inhibitors should be used with caution. Inhibitors for the UDP-Glykosyltransferases (UGT) 1A1 and 1A9 may potentially increase the exposure of the riociguat metabolite M1, which is pharmacologically active (pharmacological activity: 1/10th to 1/3rd of riociguat). For co-administration with these substances follow the recommendation on dose titration (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gefitinib (HOS-121309) erlotinib (HOS-113527) tyrosine (HOS-108875)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T01:00:00Z · SHA-256 3d1a5306a1e99b336747bac1f508fcb4f4b6128739940b8414bff8db32c20c38 · Passage bf69a5934861918c38a8f24b17c2be549a86f41790d9cf8359eeb004c9c174f9 · Zeichen 5643–6530 im Abschnitt